Aeglea BioTherapeutics is a technology company.
Aeglea BioTherapeutics has raised $44.0M across 1 funding round.
Aeglea BioTherapeutics has raised $44.0M in total across 1 funding round.
Aeglea BioTherapeutics is a clinical-stage biotechnology company developing human enzyme therapeutics for rare metabolic diseases with limited treatment options.[1] Its lead candidate, pegzilarginase, targets Arginase 1 Deficiency and met its primary endpoint in the Phase 3 PEACE study by reducing plasma arginine levels, showing positive trends in patient mobility; the company planned a Biologics License Application submission in early 2022.[1] Following acquisition of Spyre Therapeutics, Aeglea has shifted focus to inflammatory bowel disease (IBD), combining antibody engineering, therapeutic combinations, and precision immunology to improve efficacy, safety, and convenience.[2]
The company serves patients with rare genetic disorders and now IBD, addressing unmet needs in metabolic regulation and gut inflammation where current therapies fall short.[1][2] Growth momentum includes pivotal trial success, regulatory designations (Rare Pediatric Disease and Breakthrough Therapy), and strategic pivot via acquisition, positioning it for potential commercialization and expanded pipelines.[1][2]
Founded as a biotechnology firm specializing in enzyme therapies, Aeglea emerged to tackle rare metabolic diseases through engineered human enzymes.[1] Key early milestones include advancing pegzilarginase into Phase 3 trials for Arginase 1 Deficiency, a rare condition causing arginine buildup and neurological/motor impairments.[1] The PEACE study's success marked a pivotal moment, demonstrating sustained arginine reduction and mobility improvements, leading to FDA submission plans.[1]
A transformative shift occurred with the acquisition of Spyre Therapeutics, redirecting efforts toward IBD therapeutics.[2] This evolution reflects adaptation from metabolic rare diseases to broader immunology applications, leveraging Spyre's expertise in antibody engineering and precision medicine.[2]
Aeglea rides the wave of precision biotechnology, targeting rare diseases and immunology amid rising demand for enzyme/antibody therapies in underserved areas like metabolic disorders and IBD.[1][2] Timing aligns with FDA incentives for rare pediatric conditions and growing IBD prevalence, fueled by market forces like biologics advancements and unmet needs in chronic inflammation.[1] It influences the ecosystem by validating enzyme engineering for metabolic control and accelerating immunology combos, potentially lowering barriers for similar biotechs pursuing regulatory fast-tracks.[1][2]
Aeglea's trajectory hinges on pegzilarginase commercialization post-2022 BLA (if approved) and Spyre-driven IBD advances, with potential Phase 2/3 trials scaling its immunology platform.[1][2] Trends like AI-optimized antibodies and combo therapies will shape growth, amplifying its shift from rare metabolic to immunology leadership. Influence may evolve through partnerships or further acquisitions, solidifying its role in redefining enzyme and precision treatments—echoing its core mission to benefit patients with limited options.[1][2]
Aeglea BioTherapeutics has raised $44.0M in total across 1 funding round.
Aeglea BioTherapeutics's investors include RA Capital.
Aeglea BioTherapeutics has raised $44.0M across 1 funding round. Most recently, it raised $44.0M Series B in March 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2015 | $44.0M Series B | RA Capital |